As a neuroscientist and geneticist by training, Cat Lutz has worked extensively with mouse models of neurodegenerative diseases, with a focused emphasis on ALS. Her lab has worked to model in mice, many of the genetic forms of ALS and has ensured that these preclinical mouse models are available globally to the scientific community to accelerate discovery and treatments.

From 2015-2022 she established and was the Senior Director, of the In Vivo Pharmacology Efficacy Testing Service at JAX, where she designed preclinical ALS platforms for use in testing therapeutics for industry and academic partners. Cat now serves as the Vice President for the Rare Disease Translational Center at JAX, where she continues to study and develop resources for the ALS and other rare neurological disorders.